Clinical trial
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
NCT01803867
Study timeline
Study start (unknown)2013-03-01Date precision: month
Registry last updated2015-02-27
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Multiple Sclerosisunresolved
Interventions
rHIgM22DRUG
Sponsors & collaborators
Acorda Therapeuticslead sponsor
PRA Health Sciencescollaborator
Mapped research locations
SeattleWashington, United States2DallasTexas, United States1BaltimoreMaryland, United States1St LouisMissouri, United States1IndianapolisIndiana, United States1AuroraColorado, United States1RochesterNew York, United States1SacramentoCalifornia, United States1Long BeachCalifornia, United States1ProvidenceRhode Island, United States1Kansas CityKansas, United States1StanfordCalifornia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01803867 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.